Loading...
01/11 16:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: solid revenue growth and market share gains in key products are offset by cybersecurity and supply chain issues. The lack of a shareholder return plan and increased expenses are concerning. The Q&A reveals management's reluctance to provide specifics, adding uncertainty. Despite some positive product developments, the challenges and unclear guidance result in a neutral sentiment. Given the company's small market cap, the stock price is likely to remain stable, with fluctuations within the neutral range over the next two weeks.
Total Revenues $99 million, up 4% year-over-year due to growth across the product portfolio, despite a decline in preservation services.
Adjusted EBITDA $17.5 million, up approximately 1% from $17.3 million year-over-year, driven by revenue growth and cost management.
Adjusted EBITDA Margin 17.7%, relatively flat compared to the first quarter of 2024, impacted by lower revenue from preservation services and investments in sales and marketing.
Stent Graft Revenues Increased 19% on a constant currency basis year-over-year, driven by a differentiated product portfolio focused on complex segments.
On-X Revenue Grew 11% year-over-year on a constant currency basis, outpacing initial supply expectations and gaining market share.
BioGlue Revenues Grew 9% on a constant currency basis year-over-year, reflecting growth in all major markets.
Tissue Processing Revenues Declined 23% year-over-year on a constant currency basis, primarily due to a backlog caused by a cybersecurity incident.
Gross Margins 64.2%, a decrease from 64.6% in Q1 2024, due to lower revenue from higher-margin preservation services.
General and Administrative and Marketing Expenses $54.7 million, up from $30.7 million in Q1 2024, reflecting increased noncash stock-based compensation and investments in sales and marketing.
R&D Expenses $6.7 million, down from $6.9 million in Q1 2024.
Interest Expense Net of Interest Income $7.5 million, flat compared to the prior year.
Cash Approximately $37.7 million as of March 31, 2025.
Debt $314.6 million, net of $5.4 million of unamortized loan origination costs.
Net Leverage 4.0, down from 4.5 in the prior year.
AMDS Launch: Significant progress with the initial AMDS launch following FDA HDE approval, with approximately 150 facilities seeking IRB and value analysis committee approvals.
On-X Growth: On-X revenue increased 11% year-over-year, with expectations of continued market share growth due to proven clinical benefits.
Stent Graft Revenue: Stent graft revenues grew 19% on a constant currency basis, driven by a differentiated product portfolio.
BioGlue Growth: BioGlue revenues grew 9% on a constant currency basis, with growth seen in all major markets.
Market Expansion in Latin America: Latin America delivered constant currency revenue growth of 26% in Q1, driven by new regulatory approvals and commercial footprint expansion.
Market Expansion in Asia Pacific: Asia Pacific revenue grew 8% in Q1, with expectations of strong growth in the coming years.
New Market Opportunity for On-X: New data indicates a $100 million U.S. market expansion opportunity for converting bioprosthetic valves to mechanical valves.
Cybersecurity Incident Recovery: Near total return to normal operations, with significant progress in clearing the tissue processing backlog and returning On-X supply to normal levels.
Operational Efficiency: Cleared about 1/3 of the backlog by the end of Q1, with expectations to be fully caught up by the end of Q3.
Strategic Focus on AMDS: Focus on securing PMA for AMDS while commercializing the device in the U.S.
NEXUS PMA Approval: NEXUS remains on track for PMA approval in the second half of 2026, with positive trial data supporting its market potential.
Cybersecurity Incident: The company experienced a cybersecurity incident that impacted operations, leading to extended lead times in tissue processing and On-X manufacturing, resulting in a backlog of products.
Supply Chain Challenges: The company faced supply chain challenges due to the backlog in tissue processing, which declined 23% year-over-year. However, they anticipate clearing the backlog by the end of Q3 2025.
Regulatory Issues: The launch of AMDS requires multiple approvals from hospitals, including site-wide IRB and value analysis committee approvals, which could delay market penetration.
Competitive Pressures: The company is operating in a competitive market for mechanical heart valves, with a focus on capturing market share from bioprosthetic valves, which presents both an opportunity and a challenge.
Economic Factors: The company is monitoring the dynamic trade policy and tariff environment, although they currently do not anticipate a material impact on results from tariffs.
AMDS HDE Launch: Currently commercializing AMDS in the U.S. with a $150 million annual market opportunity.
On-X Heart Valve Data: Marketing clinical data showing mortality benefits in patients under 60, targeting a new $100 million annual market opportunity.
NEXUS PMA Approval: Positive 30-day data from the Endospan TRIOMPHE trial, on track for PMA approval in the second half of 2026, accessing a $150 million annual U.S. market opportunity.
2025 Revenue Guidance: Expect constant currency growth of 11% to 14%, with reported revenues between $423 million to $435 million.
2025 Adjusted EBITDA Guidance: Expected to be in the range of $84 million to $91 million, representing 18% to 28% growth over 2024.
Q2 2025 Revenue Forecast: Forecasting reported revenue between $107.5 million to $109.5 million, approximately 13% constant currency growth at the midpoint.
Shareholder Return Plan: None
The company shows strong growth across product lines, increased revenue guidance, and improved EBITDA margins. The Q&A reveals excitement around On-X's unique clinical data and AMDS's strong demand. Although management avoided specific 2026 guidance, the positive outlook for product launches and market expansions supports a positive sentiment. With a market cap of approximately $1 billion, the stock is likely to react positively, with a predicted movement of 2% to 8%.
The earnings call summary indicates strong financial performance with revenue and EBITDA growth, successful product launches, and raised guidance. Positive market sentiment is reinforced by strong regional revenue growth and improved leverage ratios. The Q&A section highlights effective product adoption and cross-selling, though some specifics were lacking. Considering the company's small-cap status, the positive performance and guidance suggest a likely stock price increase of 2% to 8%.
The earnings call presents a mixed picture: solid revenue growth and market share gains in key products are offset by cybersecurity and supply chain issues. The lack of a shareholder return plan and increased expenses are concerning. The Q&A reveals management's reluctance to provide specifics, adding uncertainty. Despite some positive product developments, the challenges and unclear guidance result in a neutral sentiment. Given the company's small market cap, the stock price is likely to remain stable, with fluctuations within the neutral range over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
